Genetic suppression and replacement

Abstract

A strategy for suppressing specifically or partially specifically an endogenous gene and introducing a replacement gene, said strategy comprising the steps of: 1. providing suppressing nucleic acids or other suppression effectors able to bind to an endogenous gene, gene transcript or gene product to be suppressed and 2. providing genomic DNA or cDNA (complete or partial) encoding a replacement gene wherein the suppressing nucleic acids are unable to bind to equivalent regions in the genomic DNA or cDNA to prevent expression of the replacement gene. The replacement nucleic acids have modifications in one or more third base (wobble) positions such that replacement nucleic acids still code for the wild type or equivalent amino acids.

Description

REFERENCE TO RELATED APPLICATIONS [0001] This application is a continuation of U.S. application Ser. No. 09 / 155,708, which was filed under 35 U.S.C. §371 for, and claims priority to, PCT / GB97 / 00929, filed Apr. 2, 1997, which claims priority to GB9606961.2, filed Apr. 2, 1996, the disclosures of which are incorporated by reference herein.FIELD OF THE INVENTION [0002] The present invention relates to a strategy for suppressing a gene. In particular the invention relates to suppression of a mutated gene that gives rise to a dominant or deleterious effect, either monogenically or polygenically. BACKGROUND OF THE INVENTION [0003] Studies of degenerative hereditary ocular conditions, including Retinitis Pigmentosa (RP) and various macular dystrophies, have resulted in a substantial elucidation of the molecular basis of these debilitating human retinal degenerations. Applying the approach of genetic linkage, x-linked RP (xlRP) genes have been localised to the short arm of the X chromosome ...

AI Technical Summary

Benefits of technology

The patent describes a new strategy for treating inherited disorders by targeting the genetic code and using gene suppression and replacement techniques. This approach allows for flexibility in targeting specific mutations and can be used for many disease mutations in a gene. The invention also relates to a medicament for suppressing deleterious alleles that contribute to disease states. The suppression effectors that can be used include nucleic acids, ribozymes, peptide nucleic acids, triple helix forming oligonucleotides, peptides, and antibodies. Overall, the invention provides a novel way to target disease-causing genes and offers potential for improved treatment outcomes.

Problems solved by technology

Strategies to differentiate between normal and disease alleles and to selectively switch off the disease allele using suppression effectors such as antisense DNA / RNA, PNAs, ribozymes, or triple helix forming DNA, targeted towards the disease mutation may be difficult in many cases—frequently disease and normal alleles differ by only a single nucleotide.

A further difficulty inhibiting development of gene therapies is the heterogeneous nature of some dominant disorders—many different mutations in the same gene give rise to a similar disease phenotype.

Development of specific gene therapies for each of these may be prohibitive in terms of cost.

Images